• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Project Delays Hurt etrials in First Quarter

Project Delays Hurt etrials in First Quarter

May 12, 2008
CenterWatch Staff

Morrisville, N.C.-based eClinical company etrials reported another challenging quarter with a drop in net service revenue of $3.7 million for the first quarter of 2008 compared to $4.1 million reported in 2007. Quarter over quarter, the company’s profit losses widen with a $2.0 million net loss for the quarter (or $0.19 per share) compared with a loss of $900,000 during the first quarter of 2007. etrials stated that its drop in revenue was partly due to new project delays, resulting in about $1 million in lost revenue.

"Despite the delayed project starts…we continue to increase studies with existing clients and add new clients. Our qualified pipeline is up nearly 50%; our close rates nearly doubled over last year; and we closed a number of multi-product solution sales with both new and existing clients. The sales metrics we follow are improving and we are where we planned to be at this stage of our sales re-engineering efforts," said etrials chief executive officer, Chip Jennings.

New product bookings for the first were also slightly down compared to the first quarter of 2007, with reportings of $4.8 million and $6.6 million respectively. And etrials booked $7 million during the last quarter of 2007. On a positive note, the company stated it held $20.3 million in backlogged business compared with $19.8 million on March 31, 2007 and $19.2 million on December 31, 2007. The company stated this reflected a trend towards fewer project cancellations and delays.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing